Decibel Therapeutics Inc. (DBTX) NASDAQ
$4.91 (0.04) (-0.81%)
Market Cap: -
As of 09/22/23 04:00 PM EDT. Market closed.
Decibel Therapeutics Inc. (DBTX)
NASDAQ
$4.91
(0.04) (-0.81%)
Market Cap: -
As of 09/22/23 04:00 PM EDT. Market closed.
decibel therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. hearing loss is the most prevalent form of sensory impairment. it is estimated that 50 million people in the u.s., and 360 million people worldwide, suffer from some type of hearing loss. hearing disorders affect people of all ages and can have a profound impact on ... read more
decibel therapeutics is a hearing company focused on discovering and developing new medicines to protect, repair and restore hearing. hearing loss is the most prevalent form of sensory impairment. it is estimated that 50 million people in the u.s., and 360 million people worldwide, suffer from some type of hearing loss. hearing disorders affect people of all ages and can have a profound impact on quality of life. by combining recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques, decibel is pioneering a comprehensive approach to defining and treating the underlying biological causes of hearing disorders, and developing a pipeline of breakthrough drugs targeted to specific indications and patients. founded by the world’s preeminent experts in inner ear biology and hearing disorders, decibel therapeutics was launched in 2015 by third rock ventures and sr one and is headquartered in boston, mass. for more inf read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Trask Anna | See Remarks | Dec 02, 2021 | Sale | $6.37 | 5,291 | 33,688 | 2,620 | Dec 06, 2021, 04:20 PM |
Trask Anna | See Remarks | Nov 03, 2021 | Sale | $8.34 | 378 | 3,152 | 7,533 | Nov 04, 2021, 08:00 AM |
Trask Anna | SEE REMARKS | Nov 02, 2021 | Sale | $8.31 | 4,913 | 40,827 | 7,911 | Nov 03, 2021, 04:16 PM |
Trask Anna | See Remarks | Oct 14, 2021 | Sale | $7.55 | 5,364 | 40,481 | 12,824 | Oct 15, 2021, 04:57 PM |
Reid Laurence | President and Chief Executive | Sep 15, 2021 | Buy | $7.64 | 10,000 | 76,400 | 25,849 | Sep 17, 2021, 09:48 PM |
ORBIMED ADVISORS LLC | Director | Feb 17, 2021 | Buy | $18.00 | 1,666,666 | 29,999,988 | 3,843,206 | Feb 19, 2021, 07:09 PM |
Foy Matthew | Director | Feb 17, 2021 | Buy | $18.00 | 150,000 | 2,700,000 | 1,183,663 | Feb 19, 2021, 06:59 PM |
Casdin Partners Master Fund, L.P. | 10% Owner | Feb 17, 2021 | Buy | $18.00 | 575,000 | 10,350,000 | 1,121,421 | Feb 19, 2021, 06:56 PM |
Thompson Peter A. | Director | Feb 17, 2021 | Buy | $18.00 | 1,666,666 | 29,999,988 | 3,843,206 | Feb 19, 2021, 06:50 PM |
GLAXOSMITHKLINE PLC | Director | Feb 17, 2021 | Buy | $18.00 | 150,000 | 2,700,000 | 1,183,663 | Feb 19, 2021, 04:50 PM |
Owner | Relationship | Date | Value($) |
Trask Anna | See Remarks | 12/02/2021 | 33,688 |
Trask Anna | See Remarks | 11/03/2021 | 3,152 |
Trask Anna | SEE REMARKS | 11/02/2021 | 40,827 |
Trask Anna | See Remarks | 10/14/2021 | 40,481 |
Reid Laurence | President and Chief Executive | 09/15/2021 | 76,400 |
ORBIMED ADVISORS LLC | Director | 02/17/2021 | 29,999,988 |
Foy Matthew | Director | 02/17/2021 | 2,700,000 |
Casdin Partners Master Fund, L.P. | 10% Owner | 02/17/2021 | 10,350,000 |
Thompson Peter A. | Director | 02/17/2021 | 29,999,988 |
GLAXOSMITHKLINE PLC | Director | 02/17/2021 | 2,700,000 |
Period of Report: 06/30/2023
10-K/10-Q Filings: View